UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Skeletal health in DYRK1A syndrome

Frontiers in neuroscience, 2024-09, Vol.18, p.1462893

2024

Volltextzugriff (PDF)

Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models

PloS one, 2022-02, Vol.17 (2), p.e0264254

2022

Volltextzugriff (PDF)

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model

Neurobiology of disease, 2024-01, Vol.190, p.106359-106359, Article 106359

2024

Volltextzugriff (PDF)

Genetic dissection of triplicated chromosome 21 orthologs yields varying skeletal traits in Down syndrome model mice

Disease models & mechanisms, 2023-04, Vol.16 (4)

2023

Volltextzugriff (PDF)

Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model

Disease models & mechanisms, 2024-09, Vol.17 (9)

2024

Volltextzugriff (PDF)

Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn

Mammalian genome, 2011-12, Vol.22 (11-12), p.685-691

2011

Volltextzugriff (PDF)

Defective Cerebellar Response to Mitogenic Hedgehog Signaling in Down's Syndrome Mice

Proceedings of the National Academy of Sciences - PNAS, 2006-01, Vol.103 (5), p.1452-1456

2006

Volltextzugriff (PDF)

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

Molecular genetics & genomic medicine, 2017-09, Vol.5 (5), p.451-465

2017

Volltextzugriff (PDF)

Compromised femoral and lumbovertebral bone in the Dp(16)1Yey Down syndrome mouse model

Bone (New York, N.Y.), 2024-04, Vol.181, p.117046-117046, Article 117046

2024

Volltextzugriff (PDF)

Skeletal dynamics of Down syndrome: A developing perspective

Bone (New York, N.Y.), 2020-04, Vol.133, p.115215-115215, Article 115215

2020

Volltextzugriff (PDF)

A new Down syndrome rat model races forward

Trends in genetics, 2022-11, Vol.38 (11), p.1101-1102

2022

Volltextzugriff (PDF)

Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a

Human molecular genetics, 2015-10, Vol.24 (20), p.5687-5696

2015

Volltextzugriff (PDF)

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice

Scientific reports, 2020-06, Vol.10 (1), p.10426-10426, Article 10426

2020

Volltextzugriff (PDF)

Influence of allelic differences in Down syndrome

Progress in brain research, 2020-01, Vol.251, p.29-54

2020

Volltextzugriff (PDF)

Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes

Pharmacology, biochemistry and behavior, 2022-06, Vol.217, p.173404-173404, Article 173404

2022

Volltextzugriff (PDF)

Understanding the basis for Down syndrome phenotypes

PLoS genetics, 2006-03, Vol.2 (3), p.e50-e50

2006

Volltextzugriff (PDF)

Current Analysis of Skeletal Phenotypes in Down Syndrome

Current osteoporosis reports, 2021-06, Vol.19 (3), p.338-346

2021

Volltextzugriff (PDF)

Perinatal Loss of Ts65Dn Down Syndrome Mice

Genetics (Austin), 2006-01, Vol.172 (1), p.437-443

2006

Volltextzugriff (PDF)

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

Physiology & behavior, 2017-08, Vol.177, p.230-241

2017

Volltextzugriff (PDF)

Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with Down syndrome

Bone (New York, N.Y.), 2020-07, Vol.136, p.115367-115367, Article 115367

2020

Volltextzugriff (PDF)

Clinical identification of feeding and swallowing disorders in 0–6 month old infants with Down syndrome

American journal of medical genetics. Part A, 2019-02, Vol.179 (2), p.177-182

2019

Volltextzugriff (PDF)

Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome

Human molecular genetics, 2016-11, Vol.25 (22), p.4856-4869

2016

Volltextzugriff (PDF)

[Letter to the editor] PCR prescreen for genotyping the Ts65Dn mouse model of Down syndrome

BioTechniques, 2010-01, Vol.48 (1), p.35-38

2010

Volltextzugriff (PDF)

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model

Pharmacology, biochemistry and behavior, 2015-11, Vol.138, p.70-79

2015

Volltextzugriff (PDF)

Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts

Genes, 2021-10, Vol.12 (11), p.1729

2021

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(70)
Tagungsberichte
(1)

Sprache

Englisch
(71)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Skeletal health in DYRK1A syndrome

Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model

Genetic dissection of triplicated chromosome 21 orthologs yields varying skeletal traits in Down syndrome model mice

Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model

Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn

Defective Cerebellar Response to Mitogenic Hedgehog Signaling in Down's Syndrome Mice

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

Compromised femoral and lumbovertebral bone in the Dp(16)1Yey Down syndrome mouse model

Skeletal dynamics of Down syndrome: A developing perspective

A new Down syndrome rat model races forward

Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice

Influence of allelic differences in Down syndrome

Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes

Understanding the basis for Down syndrome phenotypes

Current Analysis of Skeletal Phenotypes in Down Syndrome

Perinatal Loss of Ts65Dn Down Syndrome Mice

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with Down syndrome

Clinical identification of feeding and swallowing disorders in 0–6 month old infants with Down syndrome

Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome

[Letter to the editor] PCR prescreen for genotyping the Ts65Dn mouse model of Down syndrome

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model

Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts

Suchergebnisse filtern